Skip to content

Are You a Healthcare Professional?

This European website, initiated and developed by CSL Behring, has two separate sections with the aim to provide information on haemophilia for an international audience, either to European healthcare professionals or to the general public.*

Yes, I am a healthcare professional*

No, I am not a healthcare professional

*CSL Behring is legally obliged to restrict some areas of the website to healthcare professionals only. By clicking “Yes, I am a Healthcare Professional”, you confirm this statement is true and you accept all liability related to the above. If you are not a healthcare professional you can visit the section of this website for the general public.


  1. Srivastava A, Santagostino E, Dougall A, et al. WFH guideline for the management of hemophilia, 3rd edition. Haemophilia. 2020;00:1-158.
  2. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994-2004.
  3. Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519-2530.
  4. Cutter S, Molter D, Dunn S, et al. Impact of mild to severe hemophilia on education and work by US men, women, and caregivers of children with hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study. Eur J Haematol. 2017.98:18-24.
  5. Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood. 2019;133(5):407-414.
  6. Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin M ed. 2017;6,39.
  7. Mancuso ME, Lubetsky A, Pan-Petesch B, Lissitchkov T, Nagao A, Seifert W, Li Y, Santagostino E. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020;18(5):1065-1074.
  8. US Food and Drug Administration (FDA). FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors | FDA. Accessed July 2023.
  9. European Medicines Agency (EMA). Hemlibra (emcizumab). Hemlibra | European Medicines Agency ( Accessed July 2023.
  10. Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 Apr 22;137(16):2231-2242.
  11. High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455-464.
  12. McCain J. The future of gene therapy. Biotechnol Healthc. 2005;2(3):52-54,56-60.
  13. Hemophilia Federation of America (HFA). Bleeding Disorders Historical Timeline. Accessed July 14, 2023.
  14. Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273-288.
  15. National Organization for Rare Disorders (NORD). Rare Disease Database-Hemophilia B. Accessed July 14, 2023.
  16. Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis. 2020;31(3):186-192.
  17. Ay C, Feistritzer C, Rettl J, et al. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Sci Rep. 2021;11(1):12967.
  18. Pool JG, Hershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature. 1964;203:312.
  19. Morfini M. The history of clotting factor concentrates pharmacokinetics. J Clin Med. 2017;6,35.
  20. Kasper CK, Kipnis SA. Hepatitis and clotting-factor concentrates. JAMA 1972;221(5):510.
  21. White GC. Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure. Trans Am Clin Climatol Assoc. 2010;121:61-73; discussion 74-5. PMID: 20697550; PMCID: PMC2917149.
  22. European Medicines Agency (EMA). BeneFIX. Accessed July 14, 2023.
  23. European Medicines Agency (EMA). ReFacto AF. Accessed July 14, 2023.
  24. Hemophilia Federation of America (HFA). FDA approves first long-acting rFIX therapy. Accessed July 14, 2023.
  25. European Medicines Agency (EMA). Elocta. Accessed July 14, 2023.
  26. European Medicines Agency. Idelvion. Accessed July 2023.
  27. European Medicines Agency. Alprolix. Accessed July 2023.
  28. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
  29. European Medicines Agency (EMA). Roctavian. Accessed July 14, 2023.
  30. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Accessed September 5, 2023.
  31. European Medicines Agency (EMA). Hemgenix. Accessed July 14, 2023.